EMA Is Exploring How Real-World Data Can Benefit Europe’s OTC Market, Says Agency Head Rasi
Executive Summary
The European Medicines Agency is right now looking into how real-world data and evidence can be used to improve regulatory systems and extend access to OTC medicines within the European Union, the agency's executive director Guido Rasi told the recent AESGP Regulatory Conference in Amsterdam.
You may also be interested in...
EU Regulatory Round-Up: RWE Platform Proposed, Brexit Transition Update, EPI Principles Published
The latest EU regulatory developments - EMA and HMA are looking to build an EU-wide real-world data platform; EU OTC firms can operate as normal in the UK until the end of the year; EMA, HMA and the EC have published key principles on how to develop and use electronic product information for medicines marketed within the EU.
‘Late, But Not Too Late’ For OTC Industry To Join The Digital Health Revolution
Speaking during a recent webinar, IQVIA Consumer Health's Andy Tisman gave consumer health firms three pieces of sage advice to help them seize the opportunity offered by digitalization.
Switching Can Help Normalize Self-Care – PAGB’s Michelle Riddalls
Automatic switch from pharmacy to general sales list status and leveraging the power of real-world data are two ways in which the UK's switch system can be made more efficient, according to the PAGB's new senior director of Regulatory Affairs, Michelle Riddalls.